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Background: Apoptosis related proteins in early staged NSCLC seem to have prognostic value.
We studied the value of a combination of eight of those proteins in advanced NSCLC.
Patients and methods: Bronchoscopically procured tumor biopsies of NSCLC patients were
stained immunohistochemically and rated for expression of eight different cellular proteins.
Patients were treated with 60Gy radiotherapy with or without carboplatin as radiosensitizer.
Results: Apoptotic proteins in tumors that showed positive staining were the highest for Bax
(99%), Fas (92%), FasL (87%), Rb (87%), p21(WAF1) (73%), and p53 (70%), and the lowest for
c-myc (58%) and Bcl-2 (58%). In the Cox regression analysis Bcl-2 positivity (RR = 0.61, 95%
CI, 0.37—0.98, p = 0.04) was predictive for overall survival. Only Bcl-2 staining percentage
(RR10 (RR associated with an increase in stained cells of 10%) = 0.93, 95% CI, 0.89—0.99), p53
(RR10 = 0.94, 95% CI, 0.89—0.99) and FasL (RR10 = 0.92, 95% CI, 0.86—0.99) were predictive for a
longer progression-free survival. No speciﬁc constellation of apoptotic proteins was associated
with tumor response.
Conclusion: Bcl-2 expression in tumor tissue of patients with unresectable NSCLC predicts a
better overall survival, while Bcl-2, p53, and FasL expressions predict for a longer progression-
free survival.
© 2006 Elsevier Ireland Ltd. All rights reserved.
∗ Corresponding author. University Medical Center Groningen, P.O.
Box 30.001, 9700 RB Groningen, The Netherlands
Tel.: +31 50 3616161; fax: +31 50 3619320.
E-mail address: h.j.m.groen@int.umcg.nl (H.J.M. Groen).
1. Introduction
Most important prognostic factors in non-small cell lung can-
cer (NSCLC) patients are clinical parameters such as disease
0169-5002/$ — see front matter © 2006 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.lungcan.2005.12.009
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stage, performance status, and weight loss. Prognosis of
these patients is still poor. One and 5 years survival for
patients with locally unresectable NSCLC is about 27% and
6%, respectively [1]. Treatment of these patients mainly con-
sists of concurrent radiation and chemotherapy. The impact
of such therapy on prognosis depends on the tumor vol-
ume and tumor response to treatment. For instance, large
variations in cellular radiosensitivity, which correlate with
radioresponsiveness in human tumors [2,3] have been found
in tumor cells [4] and also in normal cells [5] taken from dif-
ferent individuals. Identifying biological factors that deter-
mine tumor resistance towards radiation or chemotherapy
may be helpful for optimizing therapy. Especially, variability
in the tumor cell’s ability to go into apoptosis may be cru-
cial. In vitro studies in small cell lung cancer cell lines show
that chemoradiotherapy induces morphological changes in
cell size and cell size heterogeneity which are more pro-
nounced in the sensitive GLC4 than in GLC4-CDDP tumors.
An increase in p21 in GLC4 cell line after radiationmay facili-
tate apoptosis. The increase in number of Bcl-2 positive cells
after combined treatment and the consistently negative p21
status after any treatment in the resistant GLC4-CDDP cell
line may protect these tumor cells from apoptosis as a part
of their resistance mechanism to cisplatin [6].
Nowadays, several pathways leading to apoptosis have
been revealed. For instance, upon radiation DNA damage,
the tumor suppressor gene p53 induces Bax protein expres-


































[11]. We investigated whether single or combined expres-
sion of p53, p21(WAF1), Rb, c-myc, Bcl-2, Bax, and Fas and
FasL in tumor biopsies, obtained from these patients, had
prognostic implications.
2. Patients and methods
2.1. Patients and biopsies
In a randomized study, patients with locally advanced and
inoperable NSCLC were treated with radiotherapy (60Gy)
administered as 2Gy per day for 5 days a week during 6
weeks with or without continuous intravenous carboplatin
(total dose: 860mg/m2/6 weeks) as radiosensitizer. The
study was approved by the local medical ethics commit-
tees of all hospitals and all patients gave written informed
consent. Tumor responses were measured according to WHO
criteria. Patients were followed every 3 months by history,
physical examination, chest X-ray and additional imaging
tests when there was suspicion for metastases. Overall sur-
vival was calculated from the time of randomization until
death, loss of follow-up, or end of study. Time to progression
was calculated from the time of randomization until time of
local tumor progression or the occurrence of metastases.
Tumor biopsies prior to treatment were obtained by bron-
choscopy. All biopsies were immediately ﬁxed in 10% forma-





























aene c-myc can also activate apoptosis in a p53-dependent
anner [8]. Furthermore, active p53 can also induce cell
ycle arrest via p21 (WAF1) inhibiting Rb phosphorylation.
b protein hypophosphorylation suppresses the transition
rom G1 to S phase. One observation in an interleukin-3
ependent cell line suggests that the absolute level of p21
an regulate whether a cell will arrest in G1 or goes into
poptosis [9]. Apoptosis can also be induced by death recep-
ors, such as Fas or DR4/5. Other mechanisms, such as Bcl-2
rotein members binding to Bax as heterodimers, prevent
poptosis.
Induction of apoptosis by chemotherapy or radiation
epends on the function of these proteins. It has been shown
hat these proteins can be mutated, absent, up or down reg-
lated in tumor cells. Moreover, the differential expression
f some of these proteins may elicit a speciﬁc signal path-
ay reﬂecting at least in part the heterogeneity in tumor
esponse and metastatic rate. Also effects downstream in
he apoptotic pathways can be hampered. In NSCLC for
nstance, not only the Fas receptor but also a defective
aspase-3 relocalization can inﬂuence the ability of a tumor
ell to go into apoptosis [10]. The effect of treatment may
herefore be related to the functionality and expression of
poptotic proteins. In the light of these interactions the
uestion raises whether expression of these proteins has
rognostic implications. Until now, most studies concerning
rognostic implications of expression of these proteins in
umors from NSCLC patients have been performed in tissue
btained from patients with early stage NSCLC by surgical
rocedures. In the present prospective study we obtained
umor tissue from locally unresectable stage IIIA/B NSCLC
atients treated with either radiation alone or radiation
ombined with carboplatin as radiosensitizer. The results of
he parental clinical study have been published previouslyures. From all embedded biopsies 3m sections were cut
nd placed on 3-aminopropyltriethoxysilan (APES) coated
lides.
.2. Chemicals
hosphate buffered saline (PBS, 150mM NaCl, 7.6mM
a2HPO4·2H2O, 1.6mM KH2PO4, pH 7.35) was freshly made
n our laboratory. Antigen retrieval (AR) solution consisted
f 2% blocking reagent (Roche Biochemicals, Germany) for
ucleic acid hybridization and detection with 0.2% SDS in
aleic acid buffer (pH 6.0). Tris buffer was 0.1M Tris—HCl
t pH 9.0. Bovine serum albumine (BSA) was obtained
rom Serva (Heidelberg, Germany), human AB serum was
btained from Sigma—Aldrich (Zwijndrecht, The Nether-
ands). Imidazol was purchased from Merck (Darmstadt, Ger-
any), di-ammine benzidine tetrahydrochloride (DAB) from
CN Biomedicals (Zoetermeer, The Netherlands). Mounting
edium was purchased from International Medical (Zut-
hen, The Netherlands).
.3. Tissue staining
rior to immunohistochemistry slides were deparafﬁnized
nd air dried. One slide per tumor stained with standard
aemotoxylin/eosin was revised by an independent pathol-
gist to establish whether it contained NSCLC tumor tis-
ue. For all immunohistochemistry purposes except for c-
yc staining, epitope demasking was performed by pre-
eating. Slides were covered with antigen retrieval (AR)
olution and incubated in a pressure cooker three times
or 10min at 115 ◦C with 5min cooling at room temper-
ture in between. For c-myc, AR consisted of incubation
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overnight at 80 ◦C in Tris buffer. After AR, slides were washed
with PBS, incubated for 30min with 0.3% H2O2 in PBS to
block endogenous peroxidase activity and washed again with
PBS. Subsequently, slides were incubated with the primary
antibody diluted in PBS/1% BSA for 1 h. Primary antibod-
ies used were: mouse monoclonal anti-p53, clone BP53-12-
1 from Biogenex (San Ramona, CA)(1:800); mouse mono-
clonal anti-p21, clone EA10 (WAF 1) from Calbiochem (Cam-
bridge, Massachusetts)(1:50); mouse monoclonal anti-Rb,
NCL-Rb from Novocastra Laboratories (Newcastle upon Tyne,
UK)(1:50); mouse monoclonal anti-c-myc, clone 9E10.3 from
Neomarkers, (Hoersholm, Denmark)(1:150); mouse mono-
clonal anti-Bcl-2, clone 124 from Dako (Glostrup, Den-
mark)(1:50); rabbit anti-Bax, N-20 from Santa Cruz (Heidel-
berg, Germany)(1:600); mouse monoclonal anti-Fas, clone
CH-11 from Upstate Biotechnology (Lake Placid, NY)(1:100);
mouse monoclonal anti-FasL from Transduction Laboratories
(Lexington, KY)(1:160).
Depending on the primary antibody, rabbit anti-mouse
immunoglobulin conjugated to peroxidase, goat anti-rabbit
antibody conjugated to peroxidase (both 1:50) or a biotiny-
lated rabbit anti-mouse antibody (1:300)(all from Dako) for
Fas and FasL, were used for the secondary step (diluted in
PBS/1% BSA/1% AB serum). Depending on the secondary anti-
body, goat anti-rabbit antibody conjugated to peroxidase,
rabbit anti-goat antibody conjugated to peroxidase (1:50) or
streptavidin conjugated peroxidase (1:300)(all from Dako)
were used for the tertiary step (diluted in PBS/1% BSA/1%
showed ≤10% positive cells, or showed a staining intensity
of zero or 1+ were categorized as 0 and others were cate-
gorized as 1.
2.5. Statistics
Cox regression analysis was used with the overall survival
time and progression-free survival as the outcome variables
and the eight immunohistochemical factors and patient
characteristics including treatment as covariates. The
association of these covariates and the tumor response
was evaluated by logistic regression and two-sided Fisher’s
exact test. The nominal level of statistical signiﬁcance used
was 5%.
3. Results
3.1. Patient characteristics and tumor biopsies
Bronchoscopical evaluation prior to treatment revealed that
117 patients had central endobronchial tumors out of 160
patients who entered the randomized study assessing the
radiosensitizing effect of carboplatin in stage III NSCLC.
From 95 patients tumor blocks were available for further
studies. Characteristics of the patients from whom tumor














After each step the slides were washed with PBS for
5min. To visualize the bound antibodies, slides were incu-
bated in DAB-medium (25mg DAB in 50mL PBS with 50mg
imidazole and 50l 30% H2O2) for 7min. Slides were coun-
terstained with haematoxylin for 2min and rinsed with
H2O. After dehydration slides were covered using mount-
ing medium. As positive controls for p53 and Rb, NSCLC
tumor tissue that showed positive staining in an earlier stain-
ing procedure was used. For p21 we used a positive breast
carcinoma, for c-myc a positive human ovarian tumor, for
Fas human liver tissue, for FasL human testis, and for Bcl-
2 and Bax human tonsil and inﬁltrating lymphocytes in the
tumor tissue as positive controls. As a negative control for
the staining procedure, the primary antibody was omitted.
Furthermore, normal tissue next to tumor tissue was used
as negative control for p53, p21(WAF1), and c-myc.
2.4. Staining analysis
All tumor biopsies were reviewed by an independent pathol-
ogist for presence of tumor tissue. Stained biopsies were
considered evaluable if they contained at least 100 tumor
cells. The number of stained tumor cells were counted in
representative parts of the slides. All stained tumor biop-
sies were evaluated in a semiquantitative way for inten-
sity of staining on a 5-point scale (0 = negative, 4 = strongly
positive), and localization of staining (nucleus, cytoplas-
matic or membrane). All evaluations were performed with-
out knowledge of prior treatment. Another classiﬁcation,
the positivity-intensity index, combined staining intensity
and percentage of positive cells. For this positivity-intensity
index, we choose two arbitrary categories: tumors thatere equally distributed over treatment with radiotherapy
lone and treatment with radiotherapy combined with car-
oplatin (Table 1).
.2. Immunohistochemistry
eventy-ﬁve to 89 patients out of the 95 pretreatment
atients with tumor blocks had enough evaluable tissue for
ubsequent immunohistochemical stainings. Positive tumor
tainings were highest for Bax (99%), Fas (92%), FasL (87%),
b (87%), p21(WAF1) (73%), and p53 (70%), and lowest for c-
yc (58%) and Bcl-2 (58%). Table 2 shows the staining charac-
eristics of the apoptotic proteins. Rb, p53, and p21(WAF1)
howed mainly nuclear staining as expected (Fig. 1). Bcl-
was more cytoplasmatic while Bax had both nuclear and
Table 1 Patient characteristics
Number of patients
Patients with evaluable biopsies 95
Male/female 86/9
Stage IIIA/IIIB 45/50
Performance status WHO 0/1 58/37
Histology
Squamous cell carcinoma 58
Adenocarcinoma 23
Large cell carcinoma 14
Mean weight loss in last 3 months





Tumor response/no response 43/52
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Table 2 Immunohistochemical staining results from endobronchial biopsies of stage III NSCLC patients
Variable p53 p21 Rb Bcl-2 Bax c-myc Fas FasL
Number of patientsa 89 85 86 84 80 76 80 75
Number of positive staining 62 (70%) 62 (73%) 75 (87%) 49 (58%) 79 (99%) 44 (58%) 74 (92%) 65 (87%)
Localization staining
Nuclear 58 51 62 9 26 0 7 0
Nuclear and cytoplasmatic 4 11 12 9 48 4 14 0
Cytoplasmatic 0 0 1 26 5 40 53 61
Membraneous — — — 5 — — 0 4
Staining intensity
1+ 8 13 17 20 3 17 6 12
2+ 16 46 38 18 39 23 43 23
3+ 15 3 16 11 35 4 25 24
4+ 23 0 4 0 2 0 0 6
Histology
Squamous cell
Positive staining 42 43 50 33 51 29 48 43
Negative staining 14 13 3 21 1 19 4 5
Adenocarcinoma
Positive staining 13 12 15 11 17 8 16 13
Negative staining 7 5 5 8 0 9 2 3
Large cell
Positive staining 7 7 10 5 11 7 10 9
Negative staining 6 5 3 6 0 4 0 2
a Patients with evaluable biopsies that contained at least 100 tumor cells per immuno-histochemically stained slide. Biopsy tissue
containing too much necrosis or if no proper tissue could be deﬁned were considered non-evaluable. The number of specimen are
different to the total of 95 biopsies due to availability of sufﬁcient tissue for all stainings.
cytoplasmatic localization. Fas and FasL were mainly cyto-
plasmatic (Fig. 2). Squamous cell carcinomas showed higher
percentage of positive staining for p53, p21(WAF1), Rb, and
Bcl-2 than adenocarcinoma or large cell carcinoma. No asso-
ciation was observed between loss of p21(WAF1) staining
and Rb protein (n = 69, p = 0.67), nor between p53 and Bcl-2
protein staining (n = 83, p = 1.00). Loss of p53 staining was
also not associated with the presence of Fas staining. The
F s of
m
ig. 1 Typical immunohistochemical staining of tumor biopsie
agniﬁcation 100×).p53, p21, c-myc, and Rb (immunoperoxidase staining, original
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Fig. 2 Typical immunohistochemical staining of tumor biopsies of Bcl-2, Bax, Fas, and FasL. Bax staining shows predominantly
nuclear staining (immunoperoxidase staining, original magniﬁcation 100×).
positivity-intensity index did not add additional information
over the positive/negative staining classiﬁcation.
3.3. Relation of tumor markers with prognosis and
tumor response
The Cox regression analysis with all the covariates but the
immunohistochemical factors revealed an overall survival
effect for stage (stage 3B versus stage 3A, RR = 0.63, 95%
CI, 0.43—0.92, p = 0.015) and for mediastinal lymph nodes
(N2 versus N3, RR = 1.69, 95% CI, 1.02—2.8, p = 0.043). Sub-
sequently these two variables plus the eight immunohisto-
chemical factors were entered into the regression model.
Only Bcl-2 positivity was predictive for a better survival
(RR = 0.61, 95% CI, 0.37—0.98, p = 0.04). Using progression-
free survival as outcome variable, Bcl-2 staining percent-
age (RR10 (RR associated with an increase in stained cells
of 10%) = 0.93, 95% CI, 0.89—0.99, p = 0.012), p53 staining
percentage (RR10 = 0.94, 95% CI, 0.89—0.99, p = 0.027) and
FasL staining percentage (RR10 = 0.92, 95% CI, 0.86—0.99,
p = 0.021) were predictive for a longer progression-free sur-
vival.
Tumor response was not associated with a single or com-
bination of (mechanistically related) apoptotic proteins.
Loss of Rb staining however was associated with unrespon-
siveness to radiotherapy, although the number of nonre-
sponding patients was small (n = 6).
not associated with p53 expression. Two small studies in
stage III NSCLC patients treated with radiation contrasted
with our results. Failure to stain for p53 correlated with
both response and better survival in one study [12] and
the presence of a mutated p53 gene predicted resistance
towards radiotherapy in the other study [13]. However,
most clinical pathological studies are performed in early-
staged NSCLC, where clinical risk factor associations are
made on resected specimen. In more advanced NSCLC such
studies are sparse. Larger studies in resected early staged
NSCLC patients revealed no association with p53 expression
[14,15]. Meta-analyses showed that p53 protein overexpres-
sion studied in resected NSCLC tumors is a poor prognostic
factor in NSCLC patients [16], especially in adenocarcinoma,
with a 5-year survival difference of 9.1% (95% CI, 2.3—16.0)
between patients with and without p53 protein overexpres-
sion [17].
In the present study the percentage of patients with
Bcl-2 expression was somewhat higher (58%) as compared
with other studies (about 40%). We found a survival advan-
tage after radiotherapy. No association between tumor
response after radiation and Bcl-2 expression was observed,
although positive Bcl-2 expression was related to a pro-
longed progression-free survival. This is a surprising effect
since Bcl-2 expression is normally associated with decreased
apoptosis, implying worse survival of patients with Bcl-2
expression. However, contradictory results involving prog-








Tumor suppressor proteins such as p53 and Rb are overex-
pressed in tumor tissue of the majority of locally advanced
NSCLC patients. In our study, 70% of these tumors showed
p53 overexpression, which was not related with tumor
responses after radiation. Also overall survival time wasral studies, Bcl-2 expression in NSCLC implied a better
rognosis after treatment [18—26]. In other studies, Bcl-
expression was reported as being related with worse
urvival [27,28], or reported as not related with survival
29—32].
Almost all patients expressed Bax protein in the present
tudy. As a single factor, its expression did not affect survival
n this, nor in another study [24].
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In our study, Rb was undetectable by immunohistochem-
istry in 13% of stage III NSCLC patients. Although the number
of Rb negative patients was small in this study, all these
patients did not respond to radiotherapy as measured with
CT scans. Also in another study patients with Rb negative
NSCLC tumors showed a tendency to do worse, especially
in adenocarcinomas [33]. Furthermore, signiﬁcantly more
stage III and IV NSCLC tumors had altered Rb protein expres-
sion than stage I and II [34]. This suggests that loss of Rb
expression is an indicator for worse prognosis. However,
Kwiatkowski [19] showed abnormal Rb protein expression in
79 of 242 NSCLC patients and found no prognostic impact.
The cyclin dependent kinase (CDK) inhibitor p21(WAF1)
was present in 73% of biopsies and although CDK inhibitors
are described as disruptors of the Rb pathway we found
no association between the failure to express p21 and Rb
expression. P21 did not predict survival or progression-free
survival in our study. Prognostic impact of p21 is not as inten-
sively investigated as p53 in NSCLC tumors. Studies in breast,
gastric, endometrial and head and neck cancer showed con-
tradicting results. High as well as low expression of p21 was
correlated with a short patient survival [35]. In NSCLC pos-
itive expression of p21 predicted a favorable prognosis in a
study by Shoji et al. [36]. Other CDK inhibitors such as p16
show the same contradicting results with respect to prog-
nostic signiﬁcance [37]. While loss of p16 or Rb expression
was associated with increased proliferative activity in p53
































of antibodies, recognition of different epitopes by different
antibodies used in those studies, and the different cut-off
points from where a tumor is deﬁned as positive or negative.
However, the major advantage of immunohistochemistry is
that it shows which cells in the tumor are stained and the
localization of the cellular staining, providing information
about cellular heterogeneity in tumor tissue, which is quite
extensive in NSCLC.
This study also shows high expression of apoptotic pro-
teins in tumor tissue. These proteins may be used as new
treatment targets [45]. Downregulation of Bcl-2 using anti-
sense technology or relocalisation of Fas and FasL to the cell
membrane followed by heteromerization may be examples
of such approach.
In conclusion, in the present study Bcl-2 was the most
obvious individual cellular protein with prognostic implica-
tion out of eight apoptosis related proteins in patients with
locally unresectable NSCLC.
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